Ideaya Biosciences Inc

NASDAQ:IDYA   3:59:51 PM EDT
15.63
+0.71 (+4.76%)
Products

Ideaya Announces IDE397 Clinical Program Update And ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation

Published: 07/27/2022 10:36 GMT
Ideaya Biosciences Inc (IDYA) - Ideaya Announces Ide397 Clinical Program Update and Ctdna Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation.
Ideaya Biosciences Inc - -initiated Monotherapy Expansion Cohorts With Enrollment Open for Nsclc and Esophagogastric Tumors With Mtap Deletion.
Ideaya Biosciences - Delivered Option Data Package to Gsk, Including Preclinical Data and Clinical Data From Ide397 Monotherapy Dose Escalation Study.
Ideaya Biosciences Inc - Selected Cohort 5 Dose As Its Phase 2 Expansion Dose, While It Continues to Dose Escalate Into Cohort 6.